Yumanity Therapeutics Inc

NASDAQ:YMTX   3:59:51 PM EDT
3.75
-0.08 (-2.09%)
Products, Regulatory

Yumanity Therapeutics Announces Positive Top-Line Results Of Phase 1B Clinical Trial For Ytx-7739 In Patients With Parkinson’S Disease Company Plans To Advance Program To Phase 2

Published: 11/10/2021 12:12 GMT
Yumanity Therapeutics Inc (YMTX) - Yumanity Therapeutics Announces Positive Top-line Results of Phase 1b Clinical Trial for Ytx-7739 in Patients With Parkinson’s Disease; Company Plans to Advance Program to Phase 2.
Yumanity Therapeutics Inc - Ytx-7739 Demonstrated Target Engagement in Phase 1b Clinical Trial in Patients With Mild-to-moderate Parkinson's Disease.
Yumanity Therapeutics Inc - Ytx-7739 Found to Be Generally Well Tolerated.
Yumanity Therapeutics Inc - Ytx-7739 Was Generally Well Tolerated With All Treatment Emergent Adverse Events Being Mild to Moderate in Severity.
Yumanity Therapeutics Inc - There Were No Serious Adverse Events.